Koto Ishida, MD
Vascular Neurology · New York, NYNPI 1194987768
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,779 of the $62,938 with a category attached, or 99.7%. C. R. Bard, Inc. & Subsidiaries accounts for 82.5% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $52,015, more than ten times the $123 reported in 2019. Among vascular neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $2517.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- C. R. Bard, Inc. & Subsidiaries$52K
- Bolton Medical Inc$11K
- Medtronic$123
Across 20 payments — averaging $2110.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$42K
What the payments were for
- Consulting fees$62,779100%
- Food & beverage$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| C. R. Bard, Inc. & Subsidiaries | 4 | $51,900 |
| Bolton Medical Inc | 20 | $10,915 |
| Medtronic | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,938 in reported general payments places this provider in the 95th percentile of 74 vascular neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $22,198 |
| Ezetimibe | 15 | $394 |
| Atorvastatin Calcium | 19 | $317 |
| ClopidogrelClopidogrel Bisulfate | 17 | $263 |
| Rosuvastatin Calcium | 15 | $225 |
| Lisinopril | 12 | $165 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in New York
- Aaron TansyNew York$2K
- Carolyn BrockingtonNew York$1K
- Dara JamiesonNew York$1K
- Priya NidamanuriNew York$639
- Jonathan GutermanNew York$582
- Laura SteinNew York$517
- Benjamin KummerNew York$476
- Colum AmoryNew York$405
- Qing HaoNew York$403
- Maryna SkliutNew York$302
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.